Clinical Trial Update: Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

This is a completed Phase 2 clinical trial evaluating Gleevec (imatinib) in combination with low-dose cytarabine for elderly patients with acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Gleevec (Imatinib)
• Low-dose cytarabine (Cytarabine (low-dose))

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Myeloid, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED